Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Glioblastoma 5Brain Neoplasms 4Glioma 3Central Nervous System Neoplasms 2Astrocytoma 2Oligodendroglioma 1Newly Diagnosed High Grade Glioma 1Neoplasms 1Melanoma 1Medulloblastoma 1Lymphoma, Follicular 1Gliosarcoma 1Familial ependymoma 1Ependymoma 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

Rituximab 43Cyclophosphamide 41fludarabine phosphate 24Filgrastim 19fludarabine 16Lenalidomide 15Bendamustine Hydrochloride 15Peripheral Blood Stem Cell Transplantation 14Bortezomib 13Etoposide 11ibrutinib 10Radiotherapy 10Biopsy 10venetoclax 9aldesleukin 9Vincristine 9Prednisone 9Magnetic Resonance Spectroscopy 9Vorinostat 8Specimen Handling 8Cytarabine 8Cyclosporine 8pembrolizumab 7obinutuzumab 7Paclitaxel 7Gemcitabine 7Flow Cytometry 7tanespimycin 6Tacrolimus 6Methylprednisolone 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, Follicular × Lomustine × Clear all
NCT01989052 2016-08-04

Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma

Duke University

Phase 1 Terminated
9 enrolled
CNSLymphoid

Glioma, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡